M.D. Rackham

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Alina Mares, Afjal H. Miah, Ian E. Smith et al. · Communications Biology · 2020 · 221 citations · Full text

Life Sciences, Biochemistry, Pharmacology +16

Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach

Megan H. Wright, Barbara Clough, M.D. Rackham et al. · Nature Chemistry · 2013 · 219 citations · Full text

Pharmacy, Chemical Biology, Pharmacology +13

A caged E3 ligase ligand for PROTAC-mediated protein degradation with light

Cyrille S. Kounde, Maria M. Shchepinova, Charlie N. Saunders et al. · Chemical Communications · 2020 · 127 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Design and Synthesis of High Affinity Inhibitors of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax N</i>-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)

M.D. Rackham, J.A. Brannigan, K. Rangachari et al. · Journal of Medicinal Chemistry · 2014 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Novel and Ligand-Efficient Inhibitors of Plasmodium falciparum and Plasmodium vivax<i>N</i>-Myristoyltransferase

M.D. Rackham, J.A. Brannigan, David K. Moss et al. · Journal of Medicinal Chemistry · 2012 · 72 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17